Trials / NCT05909488
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
Not yet recruiting Phase 2 / Phase 3 Cell therapy
- Sponsor
- PT. Prodia Stem Cell Indonesia
- Treatment
- 1.5 x 10^6 UC-MSC + CM; 5 x 10^6 UC-MSC + CM
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Started
- 2026-05
- Main results expected
- 2027-07
- Results posted
- Not yet
- Record last updated
- 2026-02-25
What the study is testing
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.
Where it runs
Indonesia (1)
- RSUP Dr. Sardjito, Yogyakarta, DI Yogyakarta